You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMepivacaine
Accession NumberDB00961  (APRD01094)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Structure
Thumb
Synonyms
(+-)-1-Methyl-2',6'-pipecoloxylidide
1-methyl-2',6'-pipecoloxylidide
Carbocaine
DL-Mepivacaine
Mepivacaina
Mepivacainum
N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide
N-(2,6-Dimethylphenyl)-1-methylpiperidine-2-carboxamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
3% Polocaine Dentalliquid30 mgblock/infiltrationDentsply Canada Limited2009-10-19Not applicableCanada
Carbocaineinjection, solution10 mg/mLepidural; infiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaineinjection, solution20 mg/mLinfiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaineinjection, solution10 mg/mLinfiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaineinjection, solution15 mg/mLepidural; infiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaineinjection, solution20 mg/mLepidural; infiltrationHospira, Inc.1960-03-15Not applicableUs
Carbocaine Liq 2%liquid20 mgintracaudal; epiduralSanofi Canada, Inc.1959-12-312001-08-10Canada
Carbocaine 1%solution1 %intracaudal; epiduralHospira Healthcare Corporation2001-06-01Not applicableCanada
Carbocaine 1%solution1 %block/infiltrationHospira Healthcare Corporation2001-07-15Not applicableCanada
Carbocaine 2%solution20 mgintracaudal; epiduralHospira Healthcare Corporation2001-07-15Not applicableCanada
Carbocaine 3%solution30 mgblock/infiltrationKodak Canada Inc.1993-12-312008-07-14Canada
Carbocaine 3%solution30 mgblock/infiltrationCarestream Health Canada Company2005-11-21Not applicableCanada
Carbocaine Inj Liq 10mg/mlliquid10 mgintracaudal; epiduralSterling Winthrop Inc.1992-12-311996-09-10Canada
Carbocaine Inj Liq 20mg/mlliquid20 mgintraspinalSterling Winthrop Inc.1992-12-311996-09-10Canada
Carbocaine Liq 1%liquid1 %block/infiltrationSanofi Canada, Inc.1959-12-312001-08-10Canada
Carbocaine Liq 1%liquid1 %intracaudal; epiduralSanofi Canada, Inc.1959-12-312001-08-10Canada
Isocaine HCl Inj 3%solution30 mgsubcutaneousNovocol Pharmaceutical Of Canada Inc1977-12-31Not applicableCanada
Mepivicaine Hydrochloride Injection, USP 3%solution30 mgblock/infiltrationDentsply Canada Limited1989-12-312012-07-19Canada
Scandonest 3% Plain Injliquid30 mgblock/infiltrationSeptodont1980-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carbocaineinjection, solution30 mg/mLsubcutaneousCaresteam Health, Inc.2011-01-01Not applicableUs
Iq Dental Mepivacaineinjection, solution30 mg/mLsubcutaneousIq Dental2012-08-15Not applicableUs
Isocaineinjection, solution30 mg/mLsubcutaneousNovocol Pharmaceutical of Canada, Inc.2010-08-20Not applicableUs
Mepivacaineinjection, solution30 mg/mLsubcutaneousDarby Dental Supply, LLC2011-01-14Not applicableUs
Mepivacaineinjection, solution30 mg/mLsubcutaneousBenco Dental2011-01-01Not applicableUs
Mepivacaineinjection, solution30 mg/mLsubcutaneousPatterson Dental Supply, Inc.2011-01-01Not applicableUs
Mepivacaineinjection, solution30 mg/mLsubcutaneousNovocol Pharmaceutical of Canada, Inc.2013-07-31Not applicableUs
Mepivacaineinjection, solution30 mg/mLsubcutaneousNDC, Inc.2015-04-10Not applicableUs
Mepivacaine Hydrochlorideinjection, solution30 mg/mLdental; infiltrationHospira, Inc.2008-04-28Not applicableUs
Mepivacaine Hydrochlorideinjection, solution30 mg/mLsubcutaneousSafco Dental Supply Co.2011-01-01Not applicableUs
Pearson Mepivacaineinjection, solution30 mg/mLsubcutaneousPearson Dental2012-05-15Not applicableUs
Polocaineinjection, solution20 mg/mLinfiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
Polocaineinjection, solution10 mg/mLinfiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
Polocaineinjection, solution30 mg/mLsubcutaneousDentsply Pharmaceutical1984-10-10Not applicableUs
Polocaine-mpfinjection, solution15 mg/mLepidural; infiltrationAPP Pharmaceuticals, LLC2009-07-21Not applicableUs
Polocaine-mpfinjection, solution20 mg/mLepidural; infiltrationAPP Pharmaceuticals, LLC2009-07-21Not applicableUs
Polocaine-mpfinjection, solution10 mg/mLepidural; infiltrationAPP Pharmaceuticals, LLC2009-07-20Not applicableUs
Scandonest Plaininjection, solution30 mg/mLsubcutaneousNovocol Pharmaceutical of Canada, Inc.2013-06-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ScandicaineNot Available
Brand mixtures
NameLabellerIngredients
2% Polocaine Dental With Levonordefrin 1:20,000Dentsply Canada Limited
Carbocaine 2% With Neo-cobefrinCarestream Health Canada Company
Carbocaine With Neo-cobefrinCaresteam Health, Inc.
Isocaine HCl Inj 2%Novocol Pharmaceutical Of Canada Inc
Mepivacaine Hydrochloride and LevonordefrinDarby Dental Supply, LLC
Mepivacaine With LevonordefrinPatterson Dental Supply, Inc.
Scandonest 2% Special InjSeptodont
Scandonest 2% With LevonordefrinNovocol Pharmaceutical Of Canada Inc
Scandonest LNovocol Pharmaceutical Of Canada, Inc
Salts
Name/CASStructureProperties
Mepivacaine Hydrochloride
1722-62-9
Thumb
  • InChI Key: RETIMRUQNCDCQB-UHFFFAOYNA-N
  • Monoisotopic Mass: 282.149891075
  • Average Mass: 282.809
DBSALT000478
Categories
UNIIB6E06QE59J
CAS number96-88-8
WeightAverage: 246.348
Monoisotopic: 246.173213336
Chemical FormulaC15H22N2O
InChI KeyInChIKey=INWLQCZOYSRPNW-UHFFFAOYSA-N
InChI
InChI=1S/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)
IUPAC Name
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
SMILES
CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid amides
Alternative Parents
Substituents
  • Alpha-amino acid amide
  • N-arylamide
  • Piperidinecarboxylic acid
  • Piperidinecarboxamide
  • 2-piperidinecarboxamide
  • Benzenoid
  • Piperidine
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
PharmacodynamicsMepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.
Mechanism of actionLocal anesthetics block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone.
Related Articles
AbsorptionAbsorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Volume of distributionNot Available
Protein bindingMepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.
Metabolism

Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.

Route of eliminationIt is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Half lifeThe half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
ClearanceNot Available
ToxicityThe mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mepivacaine Action PathwayDrug actionSMP00399
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9568
Blood Brain Barrier+0.9749
Caco-2 permeable+0.6836
P-glycoprotein substrateSubstrate0.7866
P-glycoprotein inhibitor IInhibitor0.6872
P-glycoprotein inhibitor IINon-inhibitor0.8665
Renal organic cation transporterNon-inhibitor0.5878
CYP450 2C9 substrateNon-substrate0.7853
CYP450 2D6 substrateSubstrate0.7423
CYP450 3A4 substrateSubstrate0.7726
CYP450 1A2 substrateNon-inhibitor0.7996
CYP450 2C9 inhibitorNon-inhibitor0.933
CYP450 2D6 inhibitorInhibitor0.6146
CYP450 2C19 inhibitorNon-inhibitor0.9387
CYP450 3A4 inhibitorNon-inhibitor0.5395
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7497
Ames testNon AMES toxic0.8252
CarcinogenicityNon-carcinogens0.9333
BiodegradationNot ready biodegradable0.939
Rat acute toxicity1.7237 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.908
hERG inhibition (predictor II)Inhibitor0.6936
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Solvay pharmaceuticals
  • Eastman kodak co
  • Hospira inc
  • Novocol pharmaceutical inc
  • Graham chemical co
  • International medication system
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Dentsply pharmaceutical
  • Deproco inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionepidural; infiltration10 mg/mL
Injection, solutionepidural; infiltration15 mg/mL
Injection, solutionepidural; infiltration20 mg/mL
Injection, solutioninfiltration10 mg/mL
Injection, solutioninfiltration20 mg/mL
Injection, solutionsubcutaneous30 mg/mL
Liquidintracaudal; epidural20 mg
Solutionblock/infiltration1 %
Solutionintracaudal; epidural1 %
Solutionintracaudal; epidural20 mg
Solutionblock/infiltration30 mg
Liquidintracaudal; epidural10 mg
Liquidintraspinal20 mg
Liquidblock/infiltration1 %
Liquidintracaudal; epidural1 %
Injection, solutionsubcutaneous
Solutionblock/infiltration
Solutionsubcutaneous30 mg
Injection, solutiondental; infiltration30 mg/mL
Liquidblock/infiltration
Liquidblock/infiltration30 mg
Prices
Unit descriptionCostUnit
Mepivacaine hcl powder318.33USD g
Mepivacaine hcl 3% cartridge0.46USD ml
Carbocaine 1% vial0.26USD ml
Polocaine 1% vial0.25USD ml
Polocaine 2% vial0.24USD ml
Carbocaine 2% vial0.19USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point150.5 °CPhysProp
water solubility7000 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.95HANSCH,C ET AL. (1995)
logS-1.55ADME Research, USCD
pKa7.7SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.621 mg/mLALOGPS
logP2.16ALOGPS
logP3.19ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)13.62ChemAxon
pKa (Strongest Basic)7.25ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.34 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity76.32 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0002-9000000000-6a3d80d214452a24ab62View in MoNA
References
Synthesis Reference

DrugSyn.org

US2799679
General ReferencesNot Available
External Links
ATC CodesN01BB53N01BB03
AHFS Codes
  • 72:00.00
PDB EntriesNot Available
FDA labelDownload (180 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with 7-Nitroindazole.
AcebutololThe serum concentration of Mepivacaine can be increased when it is combined with Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Mepivacaine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Mepivacaine.
AlprenololThe serum concentration of Mepivacaine can be increased when it is combined with Alprenolol.
AmisulprideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Aripiprazole.
ArotinololThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.
ArticaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Asenapine.
AtenololThe serum concentration of Mepivacaine can be increased when it is combined with Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Azaperone.
AzelastineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mepivacaine.
BaclofenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Barbital.
BefunololThe serum concentration of Mepivacaine can be increased when it is combined with Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Benzyl alcohol.
BetaxololThe serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.
BevantololThe serum concentration of Mepivacaine can be increased when it is combined with Bevantolol.
BisoprololThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.
BopindololThe serum concentration of Mepivacaine can be increased when it is combined with Bopindolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
BrimonidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Brotizolam.
BufuralolThe serum concentration of Mepivacaine can be increased when it is combined with Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Mepivacaine.
BupranololThe serum concentration of Mepivacaine can be increased when it is combined with Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Mepivacaine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Mepivacaine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine.
ButacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mepivacaine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Carisoprodol.
CarteololThe serum concentration of Mepivacaine can be increased when it is combined with Carteolol.
CarvedilolThe serum concentration of Mepivacaine can be increased when it is combined with Carvedilol.
CeliprololThe serum concentration of Mepivacaine can be increased when it is combined with Celiprolol.
CetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Mepivacaine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Mepivacaine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Mepivacaine.
CitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Mepivacaine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Mepivacaine.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Mepivacaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Mepivacaine.
CyclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.
CyproheptadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Mepivacaine.
DapoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mepivacaine.
DextromoramideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Mepivacaine.
DezocineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Mepivacaine.
DifenoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
DoxylamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Mepivacaine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Mepivacaine.
DrotebanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Mepivacaine.
EcgonineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Mepivacaine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Mepivacaine.
EntacaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.
EsmololThe serum concentration of Mepivacaine can be increased when it is combined with Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Mepivacaine.
EthanolMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Mepivacaine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Mepivacaine.
EthosuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.
EtoperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Mepivacaine.
FexofenadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Mepivacaine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Mepivacaine.
FluspirileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Mepivacaine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.
HalothaneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hexobarbital.
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mepivacaine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mepivacaine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Mepivacaine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
HydroxyzineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Indalpine.
IndenololThe serum concentration of Mepivacaine can be increased when it is combined with Indenolol.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Mepivacaine.
KetamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketobemidone.
LabetalolThe serum concentration of Mepivacaine can be increased when it is combined with Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levetiracetam.
LevobunololThe serum concentration of Mepivacaine can be increased when it is combined with Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Mepivacaine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Mepivacaine.
LithiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Mepivacaine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.
Lu AA21004The risk or severity of adverse effects can be increased when Mepivacaine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Melperone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Mepivacaine.
MetaxaloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Mepivacaine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Mepivacaine.
MetipranololThe serum concentration of Mepivacaine can be increased when it is combined with Metipranolol.
MetoprololThe serum concentration of Mepivacaine can be increased when it is combined with Metoprolol.
MetyrosineMepivacaine may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Mepivacaine.
MilnacipranThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
MirtazapineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Mepivacaine.
MolindoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Mepivacaine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.
NabiloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nabilone.
NadololThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Mepivacaine.
NitrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Mepivacaine.
OpiumThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Opium.
OrphenadrineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mepivacaine.
OsanetantThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mepivacaine.
OxprenololThe serum concentration of Mepivacaine can be increased when it is combined with Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Mepivacaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Mepivacaine.
OxymorphoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paliperidone.
ParaldehydeMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Mepivacaine.
ParoxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.
PenbutololThe serum concentration of Mepivacaine can be increased when it is combined with Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Mepivacaine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Mepivacaine.
PerampanelThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Mepivacaine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Mepivacaine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pimozide.
PindololThe serum concentration of Mepivacaine can be increased when it is combined with Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pomalidomide.
PractololThe serum concentration of Mepivacaine can be increased when it is combined with Practolol.
PramipexoleMepivacaine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Mepivacaine.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Mepivacaine.
PrimidoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Mepivacaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.
PromethazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Mepivacaine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Mepivacaine.
PropoxycaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Propoxycaine.
PropranololThe serum concentration of Mepivacaine can be increased when it is combined with Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Mepivacaine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Mepivacaine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Mepivacaine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.
RomifidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Romifidine.
RopiniroleMepivacaine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Mepivacaine.
RotigotineMepivacaine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mepivacaine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Mepivacaine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.
SertindoleThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sodium oxybate.
SotalolThe serum concentration of Mepivacaine can be increased when it is combined with Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Mepivacaine.
SuvorexantThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tasimelteon.
Technetium Tc-99m tilmanoceptMepivacaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Mepivacaine.
TetrabenazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tetrodotoxin.
ThalidomideMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Mepivacaine.
ThiamylalThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Mepivacaine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Mepivacaine.
ThiothixeneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tiletamine.
TimololThe serum concentration of Mepivacaine can be increased when it is combined with Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Mepivacaine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Mepivacaine.
TrazodoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Mepivacaine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Mepivacaine.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Mepivacaine.
TrimipramineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Mepivacaine.
VigabatrinThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Mepivacaine.
ZolazepamThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Mepivacaine.
ZonisamideThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity
Specific Function:
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which sodium ions may pass in accordance with their electrochemical gradient. Plays a role in neuropathic pain mechanisms.
Gene Name:
SCN10A
Uniprot ID:
Q9Y5Y9
Molecular Weight:
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Leffler A, Reckzeh J, Nau C: Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol. 2010 Mar 25;630(1-3):19-28. doi: 10.1016/j.ejphar.2009.12.027. Epub 2010 Jan 4. [PubMed:20044988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23